Literature DB >> 11053077

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000).

D E Furst, F C Breedveld, G R Burmester, J J Crofford, P Emery, M Feldmann, J R Kalden, A F Kavanaugh, E C Keystone, L G Klareskog, P E Lipsky, R N Maini, A S Russell, D L Scott, J S Smolen, L B Van de Putte, T L Visher, M H Weisman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11053077      PMCID： PMC1766614          DOI： 10.1136/ard.59.suppl_1.i1

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  4 in total

1.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

2.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

Authors:  L W Moreland; S W Baumgartner; M H Schiff; E A Tindall; R M Fleischmann; A L Weaver; R E Ettlinger; S Cohen; W J Koopman; K Mohler; M B Widmer; C M Blosch
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

3.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

Authors:  D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck
Journal:  N Engl J Med       Date:  2000-03-16       Impact factor: 91.245

Review 4.  Infliximab: a review of its use in the management of rheumatoid arthritis.

Authors:  A Markham; H M Lamb
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546
  4 in total
  4 in total

1.  Extraintestinal Complications of Inflammatory Bowel Disease.

Authors:  Ad A. van Bodegraven; Ben A. C. Dijkmans; Paul Lips; Tom J. Stoof; A. Salvador Peña; Stephan G. M. Meuwissen
Journal:  Curr Treat Options Gastroenterol       Date:  2001-06

Review 2.  Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible.

Authors:  T K Kvien; T Uhlig; I S Kristiansen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Pursuit of optimal outcomes in rheumatoid arthritis.

Authors:  David L Scott
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 4.  Current and future management approaches for rheumatoid arthritis.

Authors:  Ferdinand C Breedveld
Journal:  Arthritis Res       Date:  2002-03-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.